# US 2025/0082776 A1 · Polyanion coated lipid nanoparticles and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082776 A1
- Document ID: US20250082776A1
- Status: Published application
- Kind: A1
- Application number: 18/821,462
- Filed: 2024-08-30
- Published: 2025-03-13
- Earliest claimed: 2023-08-31
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Paula T. Hammond-Cunningham; Namita Rajesh Nabar; Tamara Gomez Dacoba
- Web page: https://patentgrep.com/patent/US20250082776A1

## CPC

- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1273: Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are nanoparticles comprising an LNP core with electrostatically adsorbed anionic polymers layered on the LNP surface. These nanoparticles comprise varying nucleic acid cargos and may further comprise targeting moieties covalently attached to the anionic polymers. Also provided are methods of administering cargo to a subject, methods of treatment, methods of editing a gene, and methods of reducing non-targeted cell uptake of nanoparticles.

## Claims

### Claim 1

A nanoparticle, comprising:
(a) a lipid nanoparticle (LNP) core comprising;
an ionizable lipid, wherein the ionizable lipid is positively charged;
a cargo;
a sterol;
a polyethylene glycol (PEG) lipid;
a phospholipid; and
an ionizable lipid; and
(b) an anionic polymer coating the LNP core;
wherein the anionic polymer is not nucleic acid-based.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The nanoparticle of claim 1, wherein the sterol is cholesterol.

### Claim 4 (depends on 1)

The nanoparticle of claim 1, wherein the PEG lipid is DMG-PEG-2000.

### Claim 5 (depends on 1)

The nanoparticle of claim 1, wherein the phospholipid is selected from 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).

### Claim 6 (depends on 1)

The nanoparticle of claim 1, wherein the ionizable lipid is selected from ALC-0315, DLin-MC3-DMA, DLin-KC2-DMA, cKK-E12, C12-200, and SM-102.

### Claim 7 (depends on 1)

The nanoparticle of claim 1, wherein the anionic polymer is carboxylated or sulfonated.

### Claim 8 (depends on 7)

The nanoparticle of claim 7, wherein the anionic polymer comprises hyaluronic acid (HA), poly-L-glutamate (PLE), poly-L-aspartate (PLD), polyacrylic acid (PAA), dextran sulfate, chondroitin sulfate, fucoidan, heparin sulfate, alginate, pegylated-poly-L-glutamic acid, pegylated-poly-L-aspartic acid, polysialic acid, carboxymethyl cellulose, methacrylate, sulfated polybeta cyclodextrin.

### Claim at position 9

9-10. (canceled)

### Claim 11 (depends on 1)

The nanoparticle of claim 1, wherein the anionic polymer is not DNA or RNA.

### Claim at position 11

12-13. (canceled)

### Claim 14 (depends on 1)

The nanoparticle of claim 1, wherein the particle does not comprise a poly-arginine polymer layer between the LNP core and the anionic polymer.

### Claim at position 13

15-19. (canceled)

### Claim 20 (depends on 1)

The nanoparticle of claim 1, wherein the cargo is DNA or RNA.

### Claim at position 15

21-24. (canceled)

### Claim 25 (depends on 1)

The nanoparticle of claim 1, further comprising a targeting moiety selected from the group consisting of an antibody, nanobody, affibody, aptamer, cyclodextrin, and a derivative or fragment thereof.

### Claim at position 17

26-32. (canceled)

### Claim 33 (depends on 25)

The nanoparticle of claim 25, wherein the targeting moiety is an antibody or nanobody selected from the group consisting of anti-CD117, anti-CD105, anti-CD90, anti-CXCR4, anti-CD45, anti-CD4, anti-CD8, anti-CD3, anti-CD19, anti-CD20, and anti-ferritin antibody or nanobody.

### Claim at position 19

34-45. (canceled)

### Claim 46 (depends on 1)

A pharmaceutical composition comprising a plurality of nanoparticles of claim 1, and a pharmaceutically acceptable excipient.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

A method of administering a cargo to a subject in need thereof, the method comprising administering to the subject a plurality of nanoparticles of claim 1.

### Claim 49 (depends on 1)

A method of delivering a cargo to a target cell, the method comprising contacting the target cell with a nanoparticle of claim 1.

### Claim at position 24

50-54. (canceled)

### Claim 55 (depends on 1)

A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a plurality of nanoparticles of claim 1.

### Claim 56

(canceled)

### Claim 57 (depends on 55)

The method of claim 55, wherein the disease is a proliferative disease, an immune disorder, or genetic disease.

### Claim at position 28

58-60. (canceled)

### Claim 61 (depends on 1)

A method of editing a gene in a cell, the method comprising contacting the cell with the nanoparticle of claim 1.

### Claim at position 30

62-69. (canceled)

### Claim 70

A method of reducing non-targeted cell uptake of a nanoparticles, the method comprising coating the nanoparticle with polyacrylic acid (PAA).

### Claim at position 32

71-75. (canceled)

### Claim 76 (depends on 1)

A kit comprising:
a plurality of nanoparticles of claim 1; and
instructions for using the plurality of nanoparticles.
